Fluorescent In Situ Hybridization As a Primary Test for HER2 Status in Breast Cancer: Controversies Reply

被引：4
|
作者：
Sauter, Guido [1 ]
Lee, James A. [2 ]
Slamon, Dennis J. [3 ]
Press, Michael F. [4 ,5 ]
机构：
[1] Univ Hamburg, Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany
[2] Altarum Inst, Ann Arbor, MI USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Keck Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 05期
关键词：
COST-EFFECTIVENESS ANALYSIS; RECEPTOR; 2; ASSESSMENT; GENE AMPLIFICATION; IMMUNOHISTOCHEMICAL ASSAY; FISH; TRASTUZUMAB; CONCORDANCE; CARCINOMAS; EXPRESSION; HERCEPTEST;
D O I：
10.1200/JCO.2009.25.3930
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E85 / E88
页数：4
相关论文
共 50 条
  • [31] Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH)
    Wang, Z.
    Bui, S.
    Wang, H.
    Su, N.
    Ma, X-J
    Luo, Y.
    Tubbs, R. R.
    LABORATORY INVESTIGATION, 2012, 92 : 72A - 72A
  • [32] Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH)
    Wang, Z.
    Bui, S.
    Wang, H.
    Su, N.
    Ma, X-J
    Luo, Y.
    Tubbs, R. R.
    MODERN PATHOLOGY, 2012, 25 : 72A - 72A
  • [33] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Stocker, Albina
    Trojan, Andreas
    Elfgen, Constanze
    Hilbers, Marie-Louis
    Moskovszky, Linda
    Varga, Zsuzsanna
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 311 - 319
  • [34] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Albina Stocker
    Andreas Trojan
    Constanze Elfgen
    Marie-Louis Hilbers
    Linda Moskovszky
    Zsuzsanna Varga
    Breast Cancer Research and Treatment, 2020, 183 : 311 - 319
  • [35] Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization
    Nakagawa, Tomoe
    Horii, Rie
    Ito, Yoshinori
    Iwase, Takuji
    Akiyama, Futoshi
    BREAST CANCER, 2016, 23 (01) : 78 - 84
  • [36] Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization
    Tomoe Nakagawa
    Rie Horii
    Yoshinori Ito
    Takuji Iwase
    Futoshi Akiyama
    Breast Cancer, 2016, 23 : 78 - 84
  • [37] Choice of primary anti-HER2 antibody affects concordance of immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) for determination of breast cancer HER2 status
    Gown, A. M.
    Goldstein, L. C.
    Barry, T. S.
    Kandalaft, P. L.
    Kussick, S. J.
    Tse, C. C.
    LABORATORY INVESTIGATION, 2008, 88 : 33A - 34A
  • [38] Choice of primary Anti-HER2 antibody affects concordance of immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) for determination of breast cancer HER2 status
    Gown, A. M.
    Goldstein, L. C.
    Barry, T. S.
    Kandalaft, P. L.
    Kussick, S. J.
    Tse, C. C.
    MODERN PATHOLOGY, 2008, 21 : 33A - 34A
  • [39] Fully Automated Fluorescent in situ Hybridization (FISH) Staining and Digital Analysis of HER2 in Breast Cancer: A Validation Study
    van der Logt, Elise M. J.
    Kuperus, Deborah A. J.
    van Setten, Jan W.
    van den Heuvel, Marius C.
    Boers, James. E.
    Schuuring, Ed
    Kibbelaar, Robby E.
    PLOS ONE, 2015, 10 (04):
  • [40] "Non-Classical" HER2 Fluorescent in Situ Hybridization Categories in Breast Cancer with Clinical-Pathologic Correlation
    Yang, Ellen
    Wu, Jessie
    Armstrong, Susan
    Mrkonjic, Miralem
    Turashvili, Gulisa
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 209 - 210
12345